---
title: "Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: APeX-2"
description: "Formulary evidence on Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: APeX-2. Covers Objective, Location and study date, Study design, Eligibility criteria, Treatment, Statistical analysis description, and 2 further headings. 15 evidence topics quoted from 4 sources."
canonical: "https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence/apex-2"
published: "2026-11-15T22:20:57-05:00"
modified: "2026-11-17T19:46:25-05:00"
---

# Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: APeX-2

<a id="heading-3.1.8"></a>

## 3.1.8 APeX-2

<a id="heading-3.1.8.1"></a>

### 3.1.8.1 Objective

<a id="topic-3.1.8.1-1"></a>

#### Treatment evaluation objective

> “efficacy, safety, and tolerability”

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.8.2"></a>

### 3.1.8.2 Location and Study Date

<a id="topic-3.1.8.2-1"></a>

#### Trial geography

> “40 sites in 11 countries”

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.8.3"></a>

### 3.1.8.3 Study Design

<a id="topic-3.1.8.3-1"></a>

#### Study design

> “multicenter, randomized, double-blind, placebo-controlled, parallel-group study”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.8.4"></a>

### 3.1.8.4 Eligibility Criteria

<a id="topic-3.1.8.4-1"></a>

#### Run-in attack requirement

> “at least two investigator-confirmed attacks”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.8.5"></a>

### 3.1.8.5 Treatment

<a id="topic-3.1.8.5-1"></a>

#### Berotralstat 110-mg and 150-mg regimens: route and administration

> “oral administration once daily, with food”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.8.6"></a>

### 3.1.8.6 Study Outcomes

<a id="heading-3.1.8.6.1"></a>

#### 3.1.8.6.1 Rationale for Using Monthly HAE Attack Rate as the Primary Endpoint

Not applicable.

<a id="heading-3.1.8.7"></a>

### 3.1.8.7 Statistical Analysis Description

<a id="heading-3.1.8.7.1"></a>

#### 3.1.8.7.1 Number of Participants (Planned and Analyzed)

<a id="topic-3.1.8.7.1-1"></a>

##### Randomized and treated populations

| Population | Participants |
| --- | --- |
| Randomized | “121” |
| Berotralstat 110 mg treated | “41” |
| Berotralstat 150 mg treated | “40” |
| Placebo treated | “39” |

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.8.7.2"></a>

#### 3.1.8.7.2 Description of Analysis Sets

<a id="topic-3.1.8.7.2-1"></a>

##### Efficacy population and model

> “Intent-to-Treat (ITT) population”
> “negative binomial regression model”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.8.8"></a>

### 3.1.8.8 Results

<a id="heading-3.1.8.8.1"></a>

#### 3.1.8.8.1 Participant Disposition

<a id="topic-3.1.8.8.1-1"></a>

##### Treatment exposure

| Population | Participants |
| --- | --- |
| Received at least one dose | “120” |

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.8.8.2"></a>

#### 3.1.8.8.2 Baseline Characteristics

<a id="topic-3.1.8.8.2-1"></a>

##### Median baseline attack rate during the prospective run-in period

> “2.9/month”

Source: [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

<a id="heading-3.1.8.8.3"></a>

#### 3.1.8.8.3 Efficacy Results

<a id="topic-3.1.8.8.3-1"></a>

##### Monthly attack rates during the 24-week comparison

| Treatment | Attacks per month |
| --- | --- |
| Berotralstat 110 mg | “1.65” |
| Berotralstat 150 mg | “1.31” |
| Placebo | “2.35” |

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.8.8.4"></a>

#### 3.1.8.8.4 Health-related Quality of Life and Patient-reported Outcomes

<a id="topic-3.1.8.8.4-1"></a>

##### AE-QoL total score at week 24 in APeX-2

> “In both APeX‐2 and APeX‐J, 43% of patients receiving berotralstat 150 mg achieved minimal clinically important difference (MCID) in Angioedema QoL (AE‐QoL) total score, compared with 17% in the placebo group at 6 months”
> “least square mean difference [LSMD] of change from baseline: −4.9 in APeX‐2 [p = 0.188]”

Source: [Caballero et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13327139/)

<a id="topic-3.1.8.8.4-2"></a>

##### Pooled APeX-2 and APeX-J post hoc analysis: AE-QoL at week 24

> “We conducted a post hoc trial analysis to evaluate the impact of berotralstat on HRQoL versus placebo through 24 weeks, and the long‐term effects of treatment up to 96 weeks, using pooled APeX‐2 and APeX‐J patient data.”
> “A total of 47 patients treated with berotralstat (40 from APeX‐2; 7 from APeX‐J) and 45 treated with placebo (39 from APeX‐2; 6 from APeX‐J) were included in the analysis.”
> “At Week 24, patients receiving berotralstat demonstrated significantly greater improvement versus placebo in AE‐QoL total (LSMD: −7.4; 95% CI: −14.3, −0.6; p < 0.05), functioning domain (LSMD: −10.9; 95% CI: −19.6, −2.3; p = 0.013), and fears/shame domain (LSMD: −8.7; 95% CI: −17.2, −0.2; p = 0.046) scores.”

Source: [Caballero et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13327139/)

<a id="topic-3.1.8.8.4-3"></a>

##### Open-label extension: quality of life through 96 weeks

> “Secondary endpoints included HAE attack rates and quality of life (QoL).”
> “Clinically meaningful improvements in QoL were also observed, with the largest improvements in the functioning domain.”

Source: [Kiani-Alikhan et al. (2024)](https://pubmed.ncbi.nlm.nih.gov/38122865/)

> “Among patients receiving berotralstat, consistent sustained improvements were observed across all AE‐QoL domains up to Week 96.”

Source: [Caballero et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13327139/)

<a id="heading-3.1.8.8.5"></a>

#### 3.1.8.8.5 Safety Results

<a id="topic-3.1.8.8.5-1"></a>

##### Serious treatment-emergent adverse events considered drug related

> “No drug-related serious treatment-emergent adverse events occurred.”

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/)

<a id="heading-3.1.8.9"></a>

### 3.1.8.9 Study Limitations

<a id="topic-3.1.8.9-1"></a>

#### Summary

The trial randomized 121 participants at 40 sites in 11 countries and treated 120: 41 received berotralstat 110 mg, 40 received berotralstat 150 mg, and 39 received placebo. Eligibility required “at least two investigator-confirmed attacks” during the run-in period, and the median baseline attack rate was 2.9 attacks per month. Efficacy was analyzed in the intent-to-treat population with a “negative binomial regression model”. The comparison does not describe outcomes over longer treatment, and groups of 39 to 41 participants limit precision for uncommon adverse events. No health-related quality of life result for this trial was identified. Berotralstat was compared with placebo only. Comparison with other prophylactic agents therefore relies on cross-trial comparison, in which differences in eligibility, baseline attack rates, and observation periods can affect the reported attack rates.

Source: [Zuraw et al. (2021)](https://pubmed.ncbi.nlm.nih.gov/33098856/); [FDA (2020)](https://www.accessdata.fda.gov/drugsatfda_docs/label/2020/214094s000lbl.pdf)

## Related pages
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Onvuzosiran (ADX-324): Prophylaxis of hereditary angioedema attacks](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/executive-summary.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/economics.md)
- [Onvuzosiran (ADX-324) in Prophylaxis of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/onvuzosiran--prophylaxis-of-hereditary-angioedema-attacks/references.md)
